eXoZymes lasse.g@exozymes.com https://exozymes.twentythree.com en-us Visualplatform http://blogs.law.harvard.edu/tech/rss eXoZymes episodic no https://exozymes.twentythree.com/files/rv0.0/sitelogo.gif https://exozymes.twentythree.com http://exozymes.twentythree.com/grow-everything-nct-as-a-superhero <p></p><p><a href="http://exozymes.twentythree.com/grow-everything-nct-as-a-superhero"><img src="http://exozymes.twentythree.com/64968561/125402581/5c80d1a5db03f623e4cbf2460585c98c/standard/download-12-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/photo/125402581 Mon, 13 Apr 2026 19:59:04 GMT Grow Everything: NCT as a Superhero? eXoZymes 00:52 <p></p><p><a href="http://exozymes.twentythree.com/grow-everything-nct-as-a-superhero"><img src="http://exozymes.twentythree.com/64968561/125402581/5c80d1a5db03f623e4cbf2460585c98c/standard/download-12-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/grow-everything-natures-secret <p></p><p><a href="http://exozymes.twentythree.com/grow-everything-natures-secret"><img src="http://exozymes.twentythree.com/64968559/125401732/8384a42b97769fc17b5f63e2d14d71f1/standard/download-30-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/photo/125401732 Mon, 13 Apr 2026 19:58:57 GMT Grow Everything: Nature's Secret Unlocked eXoZymes 00:50 <p></p><p><a href="http://exozymes.twentythree.com/grow-everything-natures-secret"><img src="http://exozymes.twentythree.com/64968559/125401732/8384a42b97769fc17b5f63e2d14d71f1/standard/download-30-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/nasdaq-damien-perriman-interview-on <p><p>CCO at eXoZymes, Damien Perriman, interviewed at Nasdaq around our NCT project:</p><p>"We’ve shown that we can go from idea to 100× pilot scale in 12 months - and hit it right the first time. That kind of speed and predictability is exactly what this industry has been missing, and it’s what turns a single success into a repeatable value engine."</p></p><p><a href="http://exozymes.twentythree.com/nasdaq-damien-perriman-interview-on"><img src="http://exozymes.twentythree.com/64968579/125329944/6cc27e0370bb13e7fceffa56a20c7fdc/standard/download-19-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/photo/125329944 Thu, 02 Apr 2026 17:31:33 GMT Nasdaq: Damien Perriman interview on NCT CCO at eXoZymes, Damien Perriman, interviewed at Nasdaq around our NCT project:"We’ve shown that we can go from idea to 100× pilot scale in 12 months - and hit it right the first time. That kind of speed and predictability is exactly what this industry has been missing, and it’s what turns a single success into a repeatable value engine." CCO at eXoZymes, Damien Perriman, interviewed at Nasdaq around our NCT project:"We’ve shown that we can go from idea to 100× pilot scale in 12 months - and hit it right the first time. That kind of speed and predictability is exactly what this... eXoZymes 04:26 <p><p>CCO at eXoZymes, Damien Perriman, interviewed at Nasdaq around our NCT project:</p><p>"We’ve shown that we can go from idea to 100× pilot scale in 12 months - and hit it right the first time. That kind of speed and predictability is exactly what this industry has been missing, and it’s what turns a single success into a repeatable value engine."</p></p><p><a href="http://exozymes.twentythree.com/nasdaq-damien-perriman-interview-on"><img src="http://exozymes.twentythree.com/64968579/125329944/6cc27e0370bb13e7fceffa56a20c7fdc/standard/download-19-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/interview-cayman-chemical-validates <p><p>Using eXoZymes' tech transfer package, Cayman Chemical advanced the protocol from a one-liter setup to a 100-liter pilot run, operating the reaction, downstream processing, and analysis independently. During the run, the team encountered real-world conditions - including pH variation and precipitation - which often cause enzyme-based processes to fail. Despite this, the reaction continued to perform reliably and delivered strong results, ultimately producing more than 500 grams of pharma-grade N-<em>trans</em>-caffeoyltyramine (NCT) at 99.6% purity, a result that is difficult to obtain in biomanufacturing without extensive purification steps. Additionally, the 99% conversion of feedstock to end product highlights a level of efficiency that is challenging to achieve and maintain in traditional biomanufacturing.</p><p></p><p>For Cayman Chemical, the outcome stood out based on prior experience as highlighted by Patrick Westcott, Director of Catalog Chemistry Production at Cayman Chemical: “<em>I’ve performed a lot of cell-based enzymatic biocatalysis over the years; it is a critical component of what we do at Cayman. One common aspect of this work is a drop in efficacy during scale-up. Anytime you move up in scale orders of magnitude, a process changes enough that it is considered a different process altogether.”</em></p><p></p><p>Westcott, continues, <em>“During the experiment, from the first sample that we took the analysis showed over a 99% conversion rate. There was some concern because I thought that that maybe was a little bit too high. So, we decided to take a second sample to see if it maintained a similar conversion rate. And we were a little surprised to find out that we actually did achieve this 99% conversion in our first 100-fold scale up of their process. That was very much an aha moment for us!</em>”</p></p><p><a href="http://exozymes.twentythree.com/interview-cayman-chemical-validates"><img src="http://exozymes.twentythree.com/64968575/122969142/d406da6a433f2b61ac7a70d1464afefe/standard/download-39-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/photo/122969142 Wed, 18 Mar 2026 13:59:35 GMT Interview: Cayman Chemical validates eXoZymes' technology and scalability Using eXoZymes' tech transfer package, Cayman Chemical advanced the protocol from a one-liter setup to a 100-liter pilot run, operating the reaction, downstream processing, and analysis independently. During the run, the team encountered real-world conditions - including pH variation and precipitation - which often cause enzyme-based processes to fail. Despite this, the reaction continued to perform reliably and delivered strong results, ultimately producing more than 500 grams of pharma-grade N-trans-caffeoyltyramine (NCT) at 99.6% purity, a result that is difficult to obtain in biomanufacturing without extensive purification steps. Additionally, the 99% conversion of feedstock to end product highlights a level of efficiency that is challenging to achieve and maintain in traditional biomanufacturing.For Cayman Chemical, the outcome stood out based on prior experience as highlighted by Patrick Westcott, Director of Catalog Chemistry Production at Cayman Chemical: “I’ve performed a lot of cell-based enzymatic biocatalysis over the years; it is a critical component of what we do at Cayman. One common aspect of this work is a drop in efficacy during scale-up. Anytime you move up in scale orders of magnitude, a process changes enough that it is considered a different process altogether.”Westcott, continues, “During the experiment, from the first sample that we took the analysis showed over a 99% conversion rate. There was some concern because I thought that that maybe was a little bit too high. So, we decided to take a second sample to see if it maintained a similar conversion rate. And we were a little surprised to find out that we actually did achieve this 99% conversion in our first 100-fold scale up of their process. That was very much an aha moment for us!” Using eXoZymes' tech transfer package, Cayman Chemical advanced the protocol from a one-liter setup to a 100-liter pilot run, operating the reaction, downstream processing, and analysis independently. During the run, the team encountered... eXoZymes 08:01 <p><p>Using eXoZymes' tech transfer package, Cayman Chemical advanced the protocol from a one-liter setup to a 100-liter pilot run, operating the reaction, downstream processing, and analysis independently. During the run, the team encountered real-world conditions - including pH variation and precipitation - which often cause enzyme-based processes to fail. Despite this, the reaction continued to perform reliably and delivered strong results, ultimately producing more than 500 grams of pharma-grade N-<em>trans</em>-caffeoyltyramine (NCT) at 99.6% purity, a result that is difficult to obtain in biomanufacturing without extensive purification steps. Additionally, the 99% conversion of feedstock to end product highlights a level of efficiency that is challenging to achieve and maintain in traditional biomanufacturing.</p><p></p><p>For Cayman Chemical, the outcome stood out based on prior experience as highlighted by Patrick Westcott, Director of Catalog Chemistry Production at Cayman Chemical: “<em>I’ve performed a lot of cell-based enzymatic biocatalysis over the years; it is a critical component of what we do at Cayman. One common aspect of this work is a drop in efficacy during scale-up. Anytime you move up in scale orders of magnitude, a process changes enough that it is considered a different process altogether.”</em></p><p></p><p>Westcott, continues, <em>“During the experiment, from the first sample that we took the analysis showed over a 99% conversion rate. There was some concern because I thought that that maybe was a little bit too high. So, we decided to take a second sample to see if it maintained a similar conversion rate. And we were a little surprised to find out that we actually did achieve this 99% conversion in our first 100-fold scale up of their process. That was very much an aha moment for us!</em>”</p></p><p><a href="http://exozymes.twentythree.com/interview-cayman-chemical-validates"><img src="http://exozymes.twentythree.com/64968575/122969142/d406da6a433f2b61ac7a70d1464afefe/standard/download-39-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/rapid-scale-up-enzyme-breakthrough <p><p>One of the biggest challenges of conventional technologies is the long timelines to advance through scale-up. </p><p></p><p>In this particular instance, the lack of chromatography and of multi-stage synthesis meant that we actually were able to move from one liter scale to a hundred liter scale in a matter of a couple of days. When we reached the end of that and we had achieved this 99% conversion, I was really surprised and really pleased with the robustness of the enzyme.</p></p><p><a href="http://exozymes.twentythree.com/rapid-scale-up-enzyme-breakthrough"><img src="http://exozymes.twentythree.com/64968566/124593826/ba74ddf7ad3b1580f91cb76544154ccc/standard/download-13-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/photo/124593826 Wed, 18 Mar 2026 13:59:23 GMT Rapid Scale-Up: Enzyme Breakthrough Achieved! (01) One of the biggest challenges of conventional technologies is the long timelines to advance through scale-up. In this particular instance, the lack of chromatography and of multi-stage synthesis meant that we actually were able to move from one liter scale to a hundred liter scale in a matter of a couple of days. When we reached the end of that and we had achieved this 99% conversion, I was really surprised and really pleased with the robustness of the enzyme. One of the biggest challenges of conventional technologies is the long timelines to advance through scale-up. In this particular instance, the lack of chromatography and of multi-stage synthesis meant that we actually were able to move from one... eXoZymes 00:24 <p><p>One of the biggest challenges of conventional technologies is the long timelines to advance through scale-up. </p><p></p><p>In this particular instance, the lack of chromatography and of multi-stage synthesis meant that we actually were able to move from one liter scale to a hundred liter scale in a matter of a couple of days. When we reached the end of that and we had achieved this 99% conversion, I was really surprised and really pleased with the robustness of the enzyme.</p></p><p><a href="http://exozymes.twentythree.com/rapid-scale-up-enzyme-breakthrough"><img src="http://exozymes.twentythree.com/64968566/124593826/ba74ddf7ad3b1580f91cb76544154ccc/standard/download-13-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/the-upside-interview-michael <p></p><p><a href="http://exozymes.twentythree.com/the-upside-interview-michael"><img src="http://exozymes.twentythree.com/64968568/118436186/a5af6e07da9e042b4ec51bbf11064afd/standard/download-141-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/photo/118436186 Tue, 18 Nov 2025 18:40:31 GMT 'The Upside' interview: Michael Heltzen & Lou Basenese eXoZymes 31:49 <p></p><p><a href="http://exozymes.twentythree.com/the-upside-interview-michael"><img src="http://exozymes.twentythree.com/64968568/118436186/a5af6e07da9e042b4ec51bbf11064afd/standard/download-141-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/the-catalyst-podcast-interview-with <p><p>The Catalyst Podcast by&nbsp;Igor Rafalovich is available here:</p><p><a target="_blank" rel="noopener noreferrer nofollow" href="https://www.youtube.com/@TheHealthcareCatalyst">https://www.youtube.com/@TheHealthcareCatalyst</a></p><p></p></p><p><a href="http://exozymes.twentythree.com/the-catalyst-podcast-interview-with"><img src="http://exozymes.twentythree.com/64968575/117485298/de8a8c4306780d5e93a151f4c0f4d126/standard/download-29-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/photo/117485298 Tue, 11 Nov 2025 18:33:33 GMT The Catalyst Podcast: Interview with CEO Michael Heltzen The Catalyst Podcast byIgor Rafalovich is available here:https://www.youtube.com/@TheHealthcareCatalyst The Catalyst Podcast byIgor Rafalovich is available here:https://www.youtube.com/@TheHealthcareCatalyst eXoZymes 41:53 <p><p>The Catalyst Podcast by&nbsp;Igor Rafalovich is available here:</p><p><a target="_blank" rel="noopener noreferrer nofollow" href="https://www.youtube.com/@TheHealthcareCatalyst">https://www.youtube.com/@TheHealthcareCatalyst</a></p><p></p></p><p><a href="http://exozymes.twentythree.com/the-catalyst-podcast-interview-with"><img src="http://exozymes.twentythree.com/64968575/117485298/de8a8c4306780d5e93a151f4c0f4d126/standard/download-29-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/inside-biotech-podcast-teaser <p></p><p><a href="http://exozymes.twentythree.com/inside-biotech-podcast-teaser"><img src="http://exozymes.twentythree.com/64968556/117040948/9495a09f63663c7ec216c7eb58c67b7f/standard/download-12-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/photo/117040948 Thu, 02 Oct 2025 22:26:20 GMT Inside Biotech podcast teaser eXoZymes 01:30 <p></p><p><a href="http://exozymes.twentythree.com/inside-biotech-podcast-teaser"><img src="http://exozymes.twentythree.com/64968556/117040948/9495a09f63663c7ec216c7eb58c67b7f/standard/download-12-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/inside-biotech-podcast-e34-michael <p><p> </p><p>Serial entrepreneur Michael Heltzen, CEO of eXoZymes, reveals how his NASDAQ-listed company is "liberating enzymes from cells" to create a new generation of chemical manufacturing. Instead of using living cells as factories, eXoZymes isolates enzymatic pathways to work as pure chemistry — achieving engineering-level control previously deemed impossible in conventional synthetic biology.</p><p></p><p> </p><p>Michael discusses eXoZymes’ AI-powered enzyme evolution, six-week development timelines, bold IPO strategy during biotech's funding winter, and applications in pharmaceuticals like NCT for liver disease. This is synthetic biology's next chapter: sustainable, scalable enzyme-based manufacturing that could replace both petrochemicals and natural harvesting. </p><p></p><p>🎧 Simplecast:</p><p><a target="_blank" rel="noopener noreferrer nofollow" href="https://inside-biotech.simplecast.com/episodes/revolutionizing-biotechnology-with-exozymes-michael-heltzen">https://inside-biotech.simplecast.com/episodes/revolutionizing-biotechnology-with-exozymes-michael-heltzen</a></p><p>🎧 Apple Podcast:</p><p><a target="_blank" rel="noopener noreferrer nofollow" href="https://podcasts.apple.com/us/podcast/inside-biotech/id1550384354?i=1000729544649">https://podcasts.apple.com/us/podcast/inside-biotech/id1550384354?i=1000729544649</a></p><p>📺 Spotify (Video Podcast):</p><p><a target="_blank" rel="noopener noreferrer nofollow" href="https://open.spotify.com/episode/3YbDB6jXEi1ge2lmh2XRP7?si=5Ah8o4udRvqamGQk4MieuQ">https://open.spotify.com/episode/3YbDB6jXEi1ge2lmh2XRP7?si=5Ah8o4udRvqamGQk4MieuQ</a></p></p><p><a href="http://exozymes.twentythree.com/inside-biotech-podcast-e34-michael"><img src="http://exozymes.twentythree.com/64968568/117036739/994d8c354465622e338a5a3d121d9e5e/standard/download-19-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/photo/117036739 Thu, 02 Oct 2025 22:20:42 GMT Inside Biotech podcast (E34): Michael Heltzen interview Serial entrepreneur Michael Heltzen, CEO of eXoZymes, reveals how his NASDAQ-listed company is "liberating enzymes from cells" to create a new generation of chemical manufacturing. Instead of using living cells as factories, eXoZymes isolates enzymatic pathways to work as pure chemistry — achieving engineering-level control previously deemed impossible in conventional synthetic biology. Michael discusses eXoZymes’ AI-powered enzyme evolution, six-week development timelines, bold IPO strategy during biotech's funding winter, and applications in pharmaceuticals like NCT for liver disease. This is synthetic biology's next chapter: sustainable, scalable enzyme-based manufacturing that could replace both petrochemicals and natural harvesting. 🎧 Simplecast:https://inside-biotech.simplecast.com/episodes/revolutionizing-biotechnology-with-exozymes-michael-heltzen🎧 Apple Podcast:https://podcasts.apple.com/us/podcast/inside-biotech/id1550384354?i=1000729544649📺 Spotify (Video Podcast):https://open.spotify.com/episode/3YbDB6jXEi1ge2lmh2XRP7?si=5Ah8o4udRvqamGQk4MieuQ Serial entrepreneur Michael Heltzen, CEO of eXoZymes, reveals how his NASDAQ-listed company is "liberating enzymes from cells" to create a new generation of chemical manufacturing. Instead of using living cells as factories, eXoZymes isolates... eXoZymes 01:05:27 <p><p> </p><p>Serial entrepreneur Michael Heltzen, CEO of eXoZymes, reveals how his NASDAQ-listed company is "liberating enzymes from cells" to create a new generation of chemical manufacturing. Instead of using living cells as factories, eXoZymes isolates enzymatic pathways to work as pure chemistry — achieving engineering-level control previously deemed impossible in conventional synthetic biology.</p><p></p><p> </p><p>Michael discusses eXoZymes’ AI-powered enzyme evolution, six-week development timelines, bold IPO strategy during biotech's funding winter, and applications in pharmaceuticals like NCT for liver disease. This is synthetic biology's next chapter: sustainable, scalable enzyme-based manufacturing that could replace both petrochemicals and natural harvesting. </p><p></p><p>🎧 Simplecast:</p><p><a target="_blank" rel="noopener noreferrer nofollow" href="https://inside-biotech.simplecast.com/episodes/revolutionizing-biotechnology-with-exozymes-michael-heltzen">https://inside-biotech.simplecast.com/episodes/revolutionizing-biotechnology-with-exozymes-michael-heltzen</a></p><p>🎧 Apple Podcast:</p><p><a target="_blank" rel="noopener noreferrer nofollow" href="https://podcasts.apple.com/us/podcast/inside-biotech/id1550384354?i=1000729544649">https://podcasts.apple.com/us/podcast/inside-biotech/id1550384354?i=1000729544649</a></p><p>📺 Spotify (Video Podcast):</p><p><a target="_blank" rel="noopener noreferrer nofollow" href="https://open.spotify.com/episode/3YbDB6jXEi1ge2lmh2XRP7?si=5Ah8o4udRvqamGQk4MieuQ">https://open.spotify.com/episode/3YbDB6jXEi1ge2lmh2XRP7?si=5Ah8o4udRvqamGQk4MieuQ</a></p></p><p><a href="http://exozymes.twentythree.com/inside-biotech-podcast-e34-michael"><img src="http://exozymes.twentythree.com/64968568/117036739/994d8c354465622e338a5a3d121d9e5e/standard/download-19-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/the-challenges-of-synbio-by <p><p>“Some of the challenges in SynBio, are the costs and the timelines. Timeline-wise, it takes a while to engineer, as the DBTL (design-build-test-learn) cycles can be anywhere from months to years. And I've seen that firsthand as I was in that industry for years and years.“</p><p>-states VP of Business Development at eXoZymes, Zachary Karl, PhD, highlighting some of the challenges of the synthetic biology space - and why he jumped at the opportunity to join eXoZymes, back in September of 2023.</p></p><p><a href="http://exozymes.twentythree.com/the-challenges-of-synbio-by"><img src="http://exozymes.twentythree.com/64968555/116308671/ec108f17f7f59384fab9c644b51b9b4f/standard/download-25-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/photo/116308671 Mon, 15 Sep 2025 22:00:17 GMT The challenges of SynBio - by Zachary Karl, PhD “Some of the challenges in SynBio, are the costs and the timelines. Timeline-wise, it takes a while to engineer, as the DBTL (design-build-test-learn) cycles can be anywhere from months to years. And I've seen that firsthand as I was in that industry for years and years.“-states VP of Business Development at eXoZymes, Zachary Karl, PhD, highlighting some of the challenges of the synthetic biology space - and why he jumped at the opportunity to join eXoZymes, back in September of 2023. “Some of the challenges in SynBio, are the costs and the timelines. Timeline-wise, it takes a while to engineer, as the DBTL (design-build-test-learn) cycles can be anywhere from months to years. And I've seen that firsthand as I was in that... eXoZymes 04:04 <p><p>“Some of the challenges in SynBio, are the costs and the timelines. Timeline-wise, it takes a while to engineer, as the DBTL (design-build-test-learn) cycles can be anywhere from months to years. And I've seen that firsthand as I was in that industry for years and years.“</p><p>-states VP of Business Development at eXoZymes, Zachary Karl, PhD, highlighting some of the challenges of the synthetic biology space - and why he jumped at the opportunity to join eXoZymes, back in September of 2023.</p></p><p><a href="http://exozymes.twentythree.com/the-challenges-of-synbio-by"><img src="http://exozymes.twentythree.com/64968555/116308671/ec108f17f7f59384fab9c644b51b9b4f/standard/download-25-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/nct-damien-on-4-grams-of-nct-with <p><p>🔬 Biomanufacturing breakthrough detailed: 4 grams of NCT produced at a 96% yield and with a purity higher than 99% 💥</p><p>Chief Commercial Officer at eXoZymes, Damien Perriman, states:</p><p>"The beauty of leading with NCT as our first push to market, is that the compound has already been self-affirmed in the market as generally recognized as safe (GRAS) for functional foods. Additionally, it has multiple potential applications across different verticals in prebiotics, dietary supplements, and pharmaceuticals. We’re ramping up NCT production scale 100X over the next six months to both deliver samples to our partners as well as prepare for tech transfer to GMP pilot scale production next year. We are ready to start partner discussions for kilogram demand in 2026 and beyond that - ton scale.”</p><p></p><p>📽️ Full story here: <a target="_blank" rel="noopener noreferrer nofollow" href="https://exozymes.com/blog/nct-breakthrough-purity">https://exozymes.com/blog/nct-breakthrough-purity</a></p><p>👉 Early access partnerships now open: <a target="_blank" rel="noopener noreferrer nofollow" href="https://exozymes.com/partners">https://exozymes.com/partners</a></p></p><p><a href="http://exozymes.twentythree.com/nct-damien-on-4-grams-of-nct-with"><img src="http://exozymes.twentythree.com/64968561/114746109/83545ba3c3a829b3c6ff9e87c2da6fd4/standard/download-20-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/photo/114746109 Tue, 29 Jul 2025 13:40:25 GMT NCT: Damien on 4 grams of NCT with over 99% purity 🔬 Biomanufacturing breakthrough detailed: 4 grams of NCT produced at a 96% yield and with a purity higher than 99% 💥Chief Commercial Officer at eXoZymes, Damien Perriman, states:"The beauty of leading with NCT as our first push to market, is that the compound has already been self-affirmed in the market as generally recognized as safe (GRAS) for functional foods. Additionally, it has multiple potential applications across different verticals in prebiotics, dietary supplements, and pharmaceuticals. We’re ramping up NCT production scale 100X over the next six months to both deliver samples to our partners as well as prepare for tech transfer to GMP pilot scale production next year. We are ready to start partner discussions for kilogram demand in 2026 and beyond that - ton scale.”📽️ Full story here: https://exozymes.com/blog/nct-breakthrough-purity👉 Early access partnerships now open: https://exozymes.com/partners 🔬 Biomanufacturing breakthrough detailed: 4 grams of NCT produced at a 96% yield and with a purity higher than 99% 💥Chief Commercial Officer at eXoZymes, Damien Perriman, states:"The beauty of leading with NCT as our first push to market, is that... eXoZymes 01:35 <p><p>🔬 Biomanufacturing breakthrough detailed: 4 grams of NCT produced at a 96% yield and with a purity higher than 99% 💥</p><p>Chief Commercial Officer at eXoZymes, Damien Perriman, states:</p><p>"The beauty of leading with NCT as our first push to market, is that the compound has already been self-affirmed in the market as generally recognized as safe (GRAS) for functional foods. Additionally, it has multiple potential applications across different verticals in prebiotics, dietary supplements, and pharmaceuticals. We’re ramping up NCT production scale 100X over the next six months to both deliver samples to our partners as well as prepare for tech transfer to GMP pilot scale production next year. We are ready to start partner discussions for kilogram demand in 2026 and beyond that - ton scale.”</p><p></p><p>📽️ Full story here: <a target="_blank" rel="noopener noreferrer nofollow" href="https://exozymes.com/blog/nct-breakthrough-purity">https://exozymes.com/blog/nct-breakthrough-purity</a></p><p>👉 Early access partnerships now open: <a target="_blank" rel="noopener noreferrer nofollow" href="https://exozymes.com/partners">https://exozymes.com/partners</a></p></p><p><a href="http://exozymes.twentythree.com/nct-damien-on-4-grams-of-nct-with"><img src="http://exozymes.twentythree.com/64968561/114746109/83545ba3c3a829b3c6ff9e87c2da6fd4/standard/download-20-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/nct-from-concept-to-gram-scale <p><p>🚀 Biomanufacturing breakthrough: Using our AI-powered, cell-free exozyme platform, we’ve gone from concept to gram-scale NCT in only 5 months!</p><p>Co-founder and VP of Development at eXoZymes, Dr. Paul Opgenorth, states,</p><p>"Going from the original proof-of-concept to lab scale validation, our goal was to make a first version of a biosolution that can produce at least one gram of NCT per batch, which we now have delivered on with an impressive 96% reaction yield. Not only does this biomanufacturing breakthrough prove the technical proficiency of our platform - but we have also accomplished this in only 5 months and with a limited budget. A timeline that’s unheard of in SynBio or anywhere, really.”</p><p>This isn’t just a milestone for NCT - it’s a validation of our 'powered by eXoZymes' biosolution platform that can unlock 100s of valuable natural products.</p><p>📽️ Full story here: <a target="_blank" rel="noopener noreferrer nofollow" href="https://exozymes.com/blog/nct-breakthrough-paul">https://exozymes.com/blog/nct-breakthrough-paul</a></p><p>👉 Early access partnerships now open: <a target="_blank" rel="noopener noreferrer nofollow" href="https://exozymes.com/partners">https://exozymes.com/partners</a></p></p><p><a href="http://exozymes.twentythree.com/nct-from-concept-to-gram-scale"><img src="http://exozymes.twentythree.com/64968578/114731142/33b6c8055886f4d06677245253150d33/standard/download-15-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/photo/114731142 Tue, 22 Jul 2025 22:01:57 GMT NCT: From concept to gram-scale quantity in only 5 months 🚀 Biomanufacturing breakthrough: Using our AI-powered, cell-free exozyme platform, we’ve gone from concept to gram-scale NCT in only 5 months!Co-founder and VP of Development at eXoZymes, Dr. Paul Opgenorth, states,"Going from the original proof-of-concept to lab scale validation, our goal was to make a first version of a biosolution that can produce at least one gram of NCT per batch, which we now have delivered on with an impressive 96% reaction yield. Not only does this biomanufacturing breakthrough prove the technical proficiency of our platform - but we have also accomplished this in only 5 months and with a limited budget. A timeline that’s unheard of in SynBio or anywhere, really.”This isn’t just a milestone for NCT - it’s a validation of our 'powered by eXoZymes' biosolution platform that can unlock 100s of valuable natural products.📽️ Full story here: https://exozymes.com/blog/nct-breakthrough-paul👉 Early access partnerships now open: https://exozymes.com/partners 🚀 Biomanufacturing breakthrough: Using our AI-powered, cell-free exozyme platform, we’ve gone from concept to gram-scale NCT in only 5 months!Co-founder and VP of Development at eXoZymes, Dr. Paul Opgenorth, states,"Going from the original... eXoZymes 01:05 <p><p>🚀 Biomanufacturing breakthrough: Using our AI-powered, cell-free exozyme platform, we’ve gone from concept to gram-scale NCT in only 5 months!</p><p>Co-founder and VP of Development at eXoZymes, Dr. Paul Opgenorth, states,</p><p>"Going from the original proof-of-concept to lab scale validation, our goal was to make a first version of a biosolution that can produce at least one gram of NCT per batch, which we now have delivered on with an impressive 96% reaction yield. Not only does this biomanufacturing breakthrough prove the technical proficiency of our platform - but we have also accomplished this in only 5 months and with a limited budget. A timeline that’s unheard of in SynBio or anywhere, really.”</p><p>This isn’t just a milestone for NCT - it’s a validation of our 'powered by eXoZymes' biosolution platform that can unlock 100s of valuable natural products.</p><p>📽️ Full story here: <a target="_blank" rel="noopener noreferrer nofollow" href="https://exozymes.com/blog/nct-breakthrough-paul">https://exozymes.com/blog/nct-breakthrough-paul</a></p><p>👉 Early access partnerships now open: <a target="_blank" rel="noopener noreferrer nofollow" href="https://exozymes.com/partners">https://exozymes.com/partners</a></p></p><p><a href="http://exozymes.twentythree.com/nct-from-concept-to-gram-scale"><img src="http://exozymes.twentythree.com/64968578/114731142/33b6c8055886f4d06677245253150d33/standard/download-15-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/slack-capital-interview-chris-1 <p><p>Last week, Slack Capital - an Australian investment research publication - released an investment report on eXoZymes accompanied by multiple interviews with our management team. This is the last of four interviews and&nbsp;is with the Chairman of our Board of Directors, Chris Marlett from MDB Capital. The interview&nbsp;focuses on MDB's process of selecting high-tech companies to take public, as well as Marlett's take on the potential of eXoZymes.</p><p></p><p>Full interview is available here:</p><p><a target="_blank" rel="noopener noreferrer nofollow" href="https://exozymes.com/blog/slack-capital-chairman">https://exozymes.com/blog/slack-capital-chairman</a></p><p></p><p>#AI #biomanufacturing #nutraceuticals #enzymes #exozymes #investmentreport</p><p></p></p><p><a href="http://exozymes.twentythree.com/slack-capital-interview-chris-1"><img src="http://exozymes.twentythree.com/64968567/113063336/8a54dd552a73c30c67dae7d1210ed98d/standard/download-17-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/photo/113063336 Fri, 23 May 2025 00:53:36 GMT Slack Capital interview: Chris Marlett, Chairman of the Board (teaser) Last week, Slack Capital - an Australian investment research publication - released an investment report on eXoZymes accompanied by multiple interviews with our management team. This is the last of four interviews andis with the Chairman of our Board of Directors, Chris Marlett from MDB Capital. The interviewfocuses on MDB's process of selecting high-tech companies to take public, as well as Marlett's take on the potential of eXoZymes.Full interview is available here:https://exozymes.com/blog/slack-capital-chairman#AI #biomanufacturing #nutraceuticals #enzymes #exozymes #investmentreport Last week, Slack Capital - an Australian investment research publication - released an investment report on eXoZymes accompanied by multiple interviews with our management team. This is the last of four interviews andis with the Chairman of our... eXoZymes 00:41 <p><p>Last week, Slack Capital - an Australian investment research publication - released an investment report on eXoZymes accompanied by multiple interviews with our management team. This is the last of four interviews and&nbsp;is with the Chairman of our Board of Directors, Chris Marlett from MDB Capital. The interview&nbsp;focuses on MDB's process of selecting high-tech companies to take public, as well as Marlett's take on the potential of eXoZymes.</p><p></p><p>Full interview is available here:</p><p><a target="_blank" rel="noopener noreferrer nofollow" href="https://exozymes.com/blog/slack-capital-chairman">https://exozymes.com/blog/slack-capital-chairman</a></p><p></p><p>#AI #biomanufacturing #nutraceuticals #enzymes #exozymes #investmentreport</p><p></p></p><p><a href="http://exozymes.twentythree.com/slack-capital-interview-chris-1"><img src="http://exozymes.twentythree.com/64968567/113063336/8a54dd552a73c30c67dae7d1210ed98d/standard/download-17-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/slack-capital-interview-chris <p><p>Last week, Slack Capital - an Australian investment research publication - released an investment report on eXoZymes accompanied by multiple interviews with our management team. This is the last of four interviews and&nbsp;is with the Chairman of our Board of Directors, Chris Marlett from MDB Capital. The interview&nbsp;focuses on MDB's process of selecting high-tech companies to take public, as well as Marlett's take on the potential of eXoZymes.</p><p></p><p>Full interview is available here:</p><p><a target="_blank" rel="noopener noreferrer nofollow" href="https://exozymes.com/blog/slack-capital-chairman">https://exozymes.com/blog/slack-capital-chairman</a></p><p></p><p>#AI #biomanufacturing #nutraceuticals #enzymes #exozymes #investmentreport</p><p></p></p><p><a href="http://exozymes.twentythree.com/slack-capital-interview-chris"><img src="http://exozymes.twentythree.com/64968559/113036645/0194df457fe4bb4c1cdfb53363db2dca/standard/download-33-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/photo/113036645 Fri, 23 May 2025 00:53:30 GMT Slack Capital interview: Chris Marlett, Chairman of the Board Last week, Slack Capital - an Australian investment research publication - released an investment report on eXoZymes accompanied by multiple interviews with our management team. This is the last of four interviews andis with the Chairman of our Board of Directors, Chris Marlett from MDB Capital. The interviewfocuses on MDB's process of selecting high-tech companies to take public, as well as Marlett's take on the potential of eXoZymes.Full interview is available here:https://exozymes.com/blog/slack-capital-chairman#AI #biomanufacturing #nutraceuticals #enzymes #exozymes #investmentreport Last week, Slack Capital - an Australian investment research publication - released an investment report on eXoZymes accompanied by multiple interviews with our management team. This is the last of four interviews andis with the Chairman of our... eXoZymes 41:06 <p><p>Last week, Slack Capital - an Australian investment research publication - released an investment report on eXoZymes accompanied by multiple interviews with our management team. This is the last of four interviews and&nbsp;is with the Chairman of our Board of Directors, Chris Marlett from MDB Capital. The interview&nbsp;focuses on MDB's process of selecting high-tech companies to take public, as well as Marlett's take on the potential of eXoZymes.</p><p></p><p>Full interview is available here:</p><p><a target="_blank" rel="noopener noreferrer nofollow" href="https://exozymes.com/blog/slack-capital-chairman">https://exozymes.com/blog/slack-capital-chairman</a></p><p></p><p>#AI #biomanufacturing #nutraceuticals #enzymes #exozymes #investmentreport</p><p></p></p><p><a href="http://exozymes.twentythree.com/slack-capital-interview-chris"><img src="http://exozymes.twentythree.com/64968559/113036645/0194df457fe4bb4c1cdfb53363db2dca/standard/download-33-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/slack-capital-interview-damien <p><p>Last week, Slack Capital - an Australian investment research publication - has released an investment report on eXoZymes accompanied by multiple interviews with our management team. This interview with our CCO, Damien Perriman, focuses on the commercialization of our platform.</p><p></p><p>Perriman states: "We're moving really quick, like things that I would expect a year to take, we're doing in weeks. That kind of blew my socks off and I started speaking to some of my colleagues, asking what if we could actually move a proof of concept so much faster than we did before? What does that mean for the type of partnerships that we could create? Or could we engage partners much sooner in the equation than we did before?"</p><p></p><p>Full interview is available here:</p><p><a target="_blank" rel="noopener noreferrer nofollow" href="https://exozymes.com/blog/slack-capital-vpofresearch">[link]</a></p><p></p><p>#AI #biomanufacturing #nutraceuticals #enzymes #exozymes #investmentreport</p></p><p><a href="http://exozymes.twentythree.com/slack-capital-interview-damien"><img src="http://exozymes.twentythree.com/64968566/112944998/2c024618c80ede999144c05f3354c46d/standard/download-34-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/photo/112944998 Wed, 21 May 2025 21:58:47 GMT Slack Capital interview: Damien Perriman, CCO Last week, Slack Capital - an Australian investment research publication - has released an investment report on eXoZymes accompanied by multiple interviews with our management team. This interview with our CCO, Damien Perriman, focuses on the commercialization of our platform.Perriman states: "We're moving really quick, like things that I would expect a year to take, we're doing in weeks. That kind of blew my socks off and I started speaking to some of my colleagues, asking what if we could actually move a proof of concept so much faster than we did before? What does that mean for the type of partnerships that we could create? Or could we engage partners much sooner in the equation than we did before?"Full interview is available here:[link]#AI #biomanufacturing #nutraceuticals #enzymes #exozymes #investmentreport Last week, Slack Capital - an Australian investment research publication - has released an investment report on eXoZymes accompanied by multiple interviews with our management team. This interview with our CCO, Damien Perriman, focuses on the... eXoZymes 54:21 <p><p>Last week, Slack Capital - an Australian investment research publication - has released an investment report on eXoZymes accompanied by multiple interviews with our management team. This interview with our CCO, Damien Perriman, focuses on the commercialization of our platform.</p><p></p><p>Perriman states: "We're moving really quick, like things that I would expect a year to take, we're doing in weeks. That kind of blew my socks off and I started speaking to some of my colleagues, asking what if we could actually move a proof of concept so much faster than we did before? What does that mean for the type of partnerships that we could create? Or could we engage partners much sooner in the equation than we did before?"</p><p></p><p>Full interview is available here:</p><p><a target="_blank" rel="noopener noreferrer nofollow" href="https://exozymes.com/blog/slack-capital-vpofresearch">[link]</a></p><p></p><p>#AI #biomanufacturing #nutraceuticals #enzymes #exozymes #investmentreport</p></p><p><a href="http://exozymes.twentythree.com/slack-capital-interview-damien"><img src="http://exozymes.twentythree.com/64968566/112944998/2c024618c80ede999144c05f3354c46d/standard/download-34-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/slack-capital-interview-damien-1 <p><p>Last week, Slack Capital - an Australian investment research publication - has released an investment report on eXoZymes accompanied by multiple interviews with our management team. This interview with our CCO, Damien Perriman, focuses on the commercialization of our platform.</p><p></p><p>Perriman states: "We're moving really quick, like things that I would expect a year to take, we're doing in weeks. That kind of blew my socks off and I started speaking to some of my colleagues, asking what if we could actually move a proof of concept so much faster than we did before? What does that mean for the type of partnerships that we could create? Or could we engage partners much sooner in the equation than we did before?"</p><p></p><p>Full interview is available here:</p><p><a target="_blank" rel="noopener noreferrer nofollow" href="https://exozymes.com/blog/slack-capital-cco">https://exozymes.com/blog/slack-capital-cco</a></p><p></p><p>#AI #biomanufacturing #nutraceuticals #enzymes #exozymes #investmentreport</p></p><p><a href="http://exozymes.twentythree.com/slack-capital-interview-damien-1"><img src="http://exozymes.twentythree.com/64968577/112945015/675694c1006337b5504e13d5aa831c50/standard/download-11-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/photo/112945015 Wed, 21 May 2025 21:58:32 GMT Slack Capital interview: Damien Perriman, CCO (teaser) Last week, Slack Capital - an Australian investment research publication - has released an investment report on eXoZymes accompanied by multiple interviews with our management team. This interview with our CCO, Damien Perriman, focuses on the commercialization of our platform.Perriman states: "We're moving really quick, like things that I would expect a year to take, we're doing in weeks. That kind of blew my socks off and I started speaking to some of my colleagues, asking what if we could actually move a proof of concept so much faster than we did before? What does that mean for the type of partnerships that we could create? Or could we engage partners much sooner in the equation than we did before?"Full interview is available here:https://exozymes.com/blog/slack-capital-cco#AI #biomanufacturing #nutraceuticals #enzymes #exozymes #investmentreport Last week, Slack Capital - an Australian investment research publication - has released an investment report on eXoZymes accompanied by multiple interviews with our management team. This interview with our CCO, Damien Perriman, focuses on the... eXoZymes 00:32 <p><p>Last week, Slack Capital - an Australian investment research publication - has released an investment report on eXoZymes accompanied by multiple interviews with our management team. This interview with our CCO, Damien Perriman, focuses on the commercialization of our platform.</p><p></p><p>Perriman states: "We're moving really quick, like things that I would expect a year to take, we're doing in weeks. That kind of blew my socks off and I started speaking to some of my colleagues, asking what if we could actually move a proof of concept so much faster than we did before? What does that mean for the type of partnerships that we could create? Or could we engage partners much sooner in the equation than we did before?"</p><p></p><p>Full interview is available here:</p><p><a target="_blank" rel="noopener noreferrer nofollow" href="https://exozymes.com/blog/slack-capital-cco">https://exozymes.com/blog/slack-capital-cco</a></p><p></p><p>#AI #biomanufacturing #nutraceuticals #enzymes #exozymes #investmentreport</p></p><p><a href="http://exozymes.twentythree.com/slack-capital-interview-damien-1"><img src="http://exozymes.twentythree.com/64968577/112945015/675694c1006337b5504e13d5aa831c50/standard/download-11-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/slack-capital-interview-dr-tyler <p></p><p><a href="http://exozymes.twentythree.com/slack-capital-interview-dr-tyler"><img src="http://exozymes.twentythree.com/64968577/112736663/8223ced9a4f18c818a853cd468591d59/standard/download-13-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/photo/112736663 Mon, 19 May 2025 00:26:52 GMT Slack Capital interview: Dr. Tyler Korman, VP of Research (teaser) eXoZymes 00:31 <p></p><p><a href="http://exozymes.twentythree.com/slack-capital-interview-dr-tyler"><img src="http://exozymes.twentythree.com/64968577/112736663/8223ced9a4f18c818a853cd468591d59/standard/download-13-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/slack-capital-interview-tyler <p><p>This week, Slack Capital - an Australian investment research publication - has released an investment report on eXoZymes accompanied by multiple interviews with our management team. This interview with our co-founder and VP of Research, Tyler Korman, PhD, focuses on the science behind our platform.</p><p>Full interview is available here:</p><p><a target="_blank" rel="noopener noreferrer nofollow" href="https://exozymes.com/blog/slack-capital-vpofresearch">https://exozymes.com/blog/slack-capital-vpofresearch</a></p><p>#AI #biomanufacturing #nutraceuticals #enzymes #exozymes #investmentreport</p></p><p><a href="http://exozymes.twentythree.com/slack-capital-interview-tyler"><img src="http://exozymes.twentythree.com/64968578/112529500/977dfa182581f23470d1084202d103df/standard/download-12-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/photo/112529500 Mon, 19 May 2025 00:26:44 GMT Slack Capital interview: Tyler Korman, VP of Research This week, Slack Capital - an Australian investment research publication - has released an investment report on eXoZymes accompanied by multiple interviews with our management team. This interview with our co-founder and VP of Research, Tyler Korman, PhD, focuses on the science behind our platform.Full interview is available here:https://exozymes.com/blog/slack-capital-vpofresearch#AI #biomanufacturing #nutraceuticals #enzymes #exozymes #investmentreport This week, Slack Capital - an Australian investment research publication - has released an investment report on eXoZymes accompanied by multiple interviews with our management team. This interview with our co-founder and VP of Research, Tyler... eXoZymes 41:57 <p><p>This week, Slack Capital - an Australian investment research publication - has released an investment report on eXoZymes accompanied by multiple interviews with our management team. This interview with our co-founder and VP of Research, Tyler Korman, PhD, focuses on the science behind our platform.</p><p>Full interview is available here:</p><p><a target="_blank" rel="noopener noreferrer nofollow" href="https://exozymes.com/blog/slack-capital-vpofresearch">https://exozymes.com/blog/slack-capital-vpofresearch</a></p><p>#AI #biomanufacturing #nutraceuticals #enzymes #exozymes #investmentreport</p></p><p><a href="http://exozymes.twentythree.com/slack-capital-interview-tyler"><img src="http://exozymes.twentythree.com/64968578/112529500/977dfa182581f23470d1084202d103df/standard/download-12-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/slack-capital-interview-michael <p><p>Today, Slack Capital - an Australian investment research publication - has released an investment report on eXoZymes. The release of the report is accompanied by an hour-long interview with our CEO, Michael Heltzen. </p><p></p><p>The full interview and link to download the report is available here:</p><p><a target="_blank" rel="noopener noreferrer nofollow" href="https://exozymes.com/blog/slack-capital-ceo">https://exozymes.com/blog/slack-capital-ceo</a></p><p></p><p>#AI #biomanufacturing #nutraceuticals #enzymes #exozymes #investmentreport </p></p><p><a href="http://exozymes.twentythree.com/slack-capital-interview-michael"><img src="http://exozymes.twentythree.com/64968566/112494247/28303e73629499850f46ead82a50ec4d/standard/download-12-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/photo/112494247 Tue, 13 May 2025 16:36:46 GMT Slack Capital interview: Michael Heltzen, CEO Today, Slack Capital - an Australian investment research publication - has released an investment report on eXoZymes. The release of the report is accompanied by an hour-long interview with our CEO, Michael Heltzen. The full interview and link to download the report is available here:https://exozymes.com/blog/slack-capital-ceo#AI #biomanufacturing #nutraceuticals #enzymes #exozymes #investmentreport Today, Slack Capital - an Australian investment research publication - has released an investment report on eXoZymes. The release of the report is accompanied by an hour-long interview with our CEO, Michael Heltzen. The full interview and link to... eXoZymes 01:07:35 <p><p>Today, Slack Capital - an Australian investment research publication - has released an investment report on eXoZymes. The release of the report is accompanied by an hour-long interview with our CEO, Michael Heltzen. </p><p></p><p>The full interview and link to download the report is available here:</p><p><a target="_blank" rel="noopener noreferrer nofollow" href="https://exozymes.com/blog/slack-capital-ceo">https://exozymes.com/blog/slack-capital-ceo</a></p><p></p><p>#AI #biomanufacturing #nutraceuticals #enzymes #exozymes #investmentreport </p></p><p><a href="http://exozymes.twentythree.com/slack-capital-interview-michael"><img src="http://exozymes.twentythree.com/64968566/112494247/28303e73629499850f46ead82a50ec4d/standard/download-12-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/slack-capital-interview-michael-1 <p><p>Today, Slack Capital - an Australian investment research publication - has released an investment report on eXoZymes. The release of the report is accompanied by an hour-long interview with our CEO, Michael Heltzen. </p><p></p><p>The full interview and link to download the report is available here:</p><p><a target="_blank" rel="noopener noreferrer nofollow" href="https://exozymes.com/blog/slack-capital-ceo">https://exozymes.com/blog/slack-capital-ceo</a></p><p></p><p>#AI #biomanufacturing #nutraceuticals #enzymes #exozymes #investmentreport </p></p><p><a href="http://exozymes.twentythree.com/slack-capital-interview-michael-1"><img src="http://exozymes.twentythree.com/64968579/112735956/ef34239d7f0662f4f1444286418786b4/standard/download-13-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/photo/112735956 Tue, 13 May 2025 16:34:43 GMT Slack Capital interview: Michael Heltzen, CEO (teaser) Today, Slack Capital - an Australian investment research publication - has released an investment report on eXoZymes. The release of the report is accompanied by an hour-long interview with our CEO, Michael Heltzen. The full interview and link to download the report is available here:https://exozymes.com/blog/slack-capital-ceo#AI #biomanufacturing #nutraceuticals #enzymes #exozymes #investmentreport Today, Slack Capital - an Australian investment research publication - has released an investment report on eXoZymes. The release of the report is accompanied by an hour-long interview with our CEO, Michael Heltzen. The full interview and link to... eXoZymes 00:35 <p><p>Today, Slack Capital - an Australian investment research publication - has released an investment report on eXoZymes. The release of the report is accompanied by an hour-long interview with our CEO, Michael Heltzen. </p><p></p><p>The full interview and link to download the report is available here:</p><p><a target="_blank" rel="noopener noreferrer nofollow" href="https://exozymes.com/blog/slack-capital-ceo">https://exozymes.com/blog/slack-capital-ceo</a></p><p></p><p>#AI #biomanufacturing #nutraceuticals #enzymes #exozymes #investmentreport </p></p><p><a href="http://exozymes.twentythree.com/slack-capital-interview-michael-1"><img src="http://exozymes.twentythree.com/64968579/112735956/ef34239d7f0662f4f1444286418786b4/standard/download-13-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/ai-transforming-biotechnology-from <p><p>Co-founder and VP of Development at eXoZymes, Dr. Paul Opgenorth, states:</p><p></p><p>"The Large Language Models (LLMs) actually got to learn our vocabulary by breaking down the English language to its core constituents - the 26 letters of the alphabet. Then the LLM identifies patterns and stitches the letters together in order to coherently answer the questions we give it. Conversely, you can think of enzymes in the same way. Enzymes are made up of 20 amino acids and LLMs can make the same correlations between these amino acids to get to stable structures. We can use these stable structures to make better enzymes and even select for properties that would up-classify them to exozymes."</p><p></p><p>Full story:</p><p><a target="_blank" rel="noopener noreferrer nofollow" href="https://exozymes.com/blog/alphafold-to-exozymes">https://exozymes.com/blog/alphafold-to-exozymes</a></p><p>#enzymes #exozymes #biomade #alphafold #proteinstructure&nbsp;</p></p><p><a href="http://exozymes.twentythree.com/ai-transforming-biotechnology-from"><img src="http://exozymes.twentythree.com/64968568/112222080/907d40ec2fa6184b4e8499629bfb2e3e/standard/download-21-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/photo/112222080 Mon, 28 Apr 2025 20:47:39 GMT AI transforming biotechnology: From form with AlphaFold to function with... Co-founder and VP of Development at eXoZymes, Dr. Paul Opgenorth, states:"The Large Language Models (LLMs) actually got to learn our vocabulary by breaking down the English language to its core constituents - the 26 letters of the alphabet. Then the LLM identifies patterns and stitches the letters together in order to coherently answer the questions we give it. Conversely, you can think of enzymes in the same way. Enzymes are made up of 20 amino acids and LLMs can make the same correlations between these amino acids to get to stable structures. We can use these stable structures to make better enzymes and even select for properties that would up-classify them to exozymes."Full story:https://exozymes.com/blog/alphafold-to-exozymes#enzymes #exozymes #biomade #alphafold #proteinstructure Co-founder and VP of Development at eXoZymes, Dr. Paul Opgenorth, states:"The Large Language Models (LLMs) actually got to learn our vocabulary by breaking down the English language to its core constituents - the 26 letters of the alphabet. Then... eXoZymes 04:04 <p><p>Co-founder and VP of Development at eXoZymes, Dr. Paul Opgenorth, states:</p><p></p><p>"The Large Language Models (LLMs) actually got to learn our vocabulary by breaking down the English language to its core constituents - the 26 letters of the alphabet. Then the LLM identifies patterns and stitches the letters together in order to coherently answer the questions we give it. Conversely, you can think of enzymes in the same way. Enzymes are made up of 20 amino acids and LLMs can make the same correlations between these amino acids to get to stable structures. We can use these stable structures to make better enzymes and even select for properties that would up-classify them to exozymes."</p><p></p><p>Full story:</p><p><a target="_blank" rel="noopener noreferrer nofollow" href="https://exozymes.com/blog/alphafold-to-exozymes">https://exozymes.com/blog/alphafold-to-exozymes</a></p><p>#enzymes #exozymes #biomade #alphafold #proteinstructure&nbsp;</p></p><p><a href="http://exozymes.twentythree.com/ai-transforming-biotechnology-from"><img src="http://exozymes.twentythree.com/64968568/112222080/907d40ec2fa6184b4e8499629bfb2e3e/standard/download-21-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/bloomberg-tv-interview-with-tyler-1 <p></p><p><a href="http://exozymes.twentythree.com/bloomberg-tv-interview-with-tyler-1"><img src="http://exozymes.twentythree.com/64968578/111817046/b2ef30ed519c94858379ec8c6ac92b91/standard/download-18-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/photo/111817046 Tue, 15 Apr 2025 15:14:57 GMT Bloomberg TV interview with Tyler Korman, co-founder and VP of Research eXoZymes 06:09 <p></p><p><a href="http://exozymes.twentythree.com/bloomberg-tv-interview-with-tyler-1"><img src="http://exozymes.twentythree.com/64968578/111817046/b2ef30ed519c94858379ec8c6ac92b91/standard/download-18-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/fox-business-interview-with-chief <p></p><p><a href="http://exozymes.twentythree.com/fox-business-interview-with-chief"><img src="http://exozymes.twentythree.com/64968580/110856545/48f5455527ede1c9429c5afa9dc55fc4/standard/download-28-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/photo/110856545 Mon, 17 Mar 2025 15:41:09 GMT Fox Business: Interview with Chief Market Strategist, Lou Basenese eXoZymes 07:22 <p></p><p><a href="http://exozymes.twentythree.com/fox-business-interview-with-chief"><img src="http://exozymes.twentythree.com/64968580/110856545/48f5455527ede1c9429c5afa9dc55fc4/standard/download-28-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/fox-business-interview-with-ceo <p><p></p> </p><p><a href="http://exozymes.twentythree.com/fox-business-interview-with-ceo"><img src="http://exozymes.twentythree.com/64968566/110849024/d61ced71de6ce1f26413933e66c3d488/standard/download-29-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/photo/110849024 Thu, 13 Mar 2025 21:58:14 GMT Fox Business interview with CEO Michael Heltzen eXoZymes 07:38 <p><p></p> </p><p><a href="http://exozymes.twentythree.com/fox-business-interview-with-ceo"><img src="http://exozymes.twentythree.com/64968566/110849024/d61ced71de6ce1f26413933e66c3d488/standard/download-29-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/how-exozymes-started-interviews <p><p>Interviews with eXoZymes co-founders, Tyler Korman, PhD - and - Paul Opgenorth, PhD, sharing how the basic idea - liberating the enzymes from the confines of working in cells - was hatched in Jim Bowie's lab at UCLA, before being spun out as Invizyne Technologies in 2019 (rebranded to eXoZymes in 2025), including some of the projects and challenges along the way.</p> </p><p><a href="http://exozymes.twentythree.com/how-exozymes-started-interviews"><img src="http://exozymes.twentythree.com/64968570/110628808/cef80cbbdf8b686eb04f59b8bdd8af3e/standard/download-10-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/photo/110628808 Mon, 10 Mar 2025 20:40:01 GMT How eXoZymes started: Interviews with Tyler Korman and Paul Opgenorth Interviews with eXoZymes co-founders, Tyler Korman, PhD - and - Paul Opgenorth, PhD, sharing how the basic idea - liberating the enzymes from the confines of working in cells - was hatched in Jim Bowie's lab at UCLA, before being spun out as Invizyne Technologies in 2019 (rebranded to eXoZymes in 2025), including some of the projects and challenges along the way. Interviews with eXoZymes co-founders, Tyler Korman, PhD - and - Paul Opgenorth, PhD, sharing how the basic idea - liberating the enzymes from the confines of working in cells - was hatched in Jim Bowie's lab at UCLA, before being spun out as... eXoZymes 06:54 <p><p>Interviews with eXoZymes co-founders, Tyler Korman, PhD - and - Paul Opgenorth, PhD, sharing how the basic idea - liberating the enzymes from the confines of working in cells - was hatched in Jim Bowie's lab at UCLA, before being spun out as Invizyne Technologies in 2019 (rebranded to eXoZymes in 2025), including some of the projects and challenges along the way.</p> </p><p><a href="http://exozymes.twentythree.com/how-exozymes-started-interviews"><img src="http://exozymes.twentythree.com/64968570/110628808/cef80cbbdf8b686eb04f59b8bdd8af3e/standard/download-10-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/looking-at-the-rest-of-2025-part <p><p>In this video - recorded on Dec 29, 2024 - MDB Capital Group’s&nbsp;Lou&nbsp;Basenese&nbsp;interviews&nbsp;Invizyne Technologies’ CEO&nbsp;Michael Heltzen&nbsp;about the Invizyne’s plans for the rest of 2025.</p> <p style="text-align: start">&nbsp;</p> <p style="text-align: start">“<em>There is a rebranding effort coming up very soon where we will be basically not just introducing ourselves with a new name, but also with a new way of explaining exactly what it is we're doing as a company in a way that is easier to understand and why that has value. On top of that, we can't just look like everybody else when we are so fundamentally different. So we will make sure that both in communication, but also in look and feel that we make sure people can remember us and our value proposition</em>.” said Heltzen.&nbsp;</p> </p><p><a href="http://exozymes.twentythree.com/looking-at-the-rest-of-2025-part"><img src="http://exozymes.twentythree.com/64968578/109773190/35117a9310612d28402aa73d80a09efa/standard/download-16-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/photo/109773190 Tue, 11 Feb 2025 04:07:15 GMT Looking at the rest of 2025 - part 4 of a fireside chat about Invizyne In this video - recorded on Dec 29, 2024 - MDB Capital Group’sLouBaseneseinterviewsInvizyne Technologies’ CEOMichael Heltzenabout the Invizyne’s plans for the rest of 2025. “There is a rebranding effort coming up very soon where we will be basically not just introducing ourselves with a new name, but also with a new way of explaining exactly what it is we're doing as a company in a way that is easier to understand and why that has value. On top of that, we can't just look like everybody else when we are so fundamentally different. So we will make sure that both in communication, but also in look and feel that we make sure people can remember us and our value proposition.” said Heltzen. In this video - recorded on Dec 29, 2024 - MDB Capital Group’sLouBaseneseinterviewsInvizyne Technologies’ CEOMichael Heltzenabout the Invizyne’s plans for the rest of 2025. “There is a rebranding effort coming up very soon where we will be... eXoZymes 08:27 <p><p>In this video - recorded on Dec 29, 2024 - MDB Capital Group’s&nbsp;Lou&nbsp;Basenese&nbsp;interviews&nbsp;Invizyne Technologies’ CEO&nbsp;Michael Heltzen&nbsp;about the Invizyne’s plans for the rest of 2025.</p> <p style="text-align: start">&nbsp;</p> <p style="text-align: start">“<em>There is a rebranding effort coming up very soon where we will be basically not just introducing ourselves with a new name, but also with a new way of explaining exactly what it is we're doing as a company in a way that is easier to understand and why that has value. On top of that, we can't just look like everybody else when we are so fundamentally different. So we will make sure that both in communication, but also in look and feel that we make sure people can remember us and our value proposition</em>.” said Heltzen.&nbsp;</p> </p><p><a href="http://exozymes.twentythree.com/looking-at-the-rest-of-2025-part"><img src="http://exozymes.twentythree.com/64968578/109773190/35117a9310612d28402aa73d80a09efa/standard/download-16-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/go-to-market-strategy-part-3-of-a-1 <p><p>In this video - recorded on Dec 29, 2024 - MDB Capital Group’s&nbsp;Lou&nbsp;Basenese&nbsp;interviews&nbsp;Invizyne Technologies’ CEO&nbsp;Michael Heltzen&nbsp;about the Invizyne’s Go To Market strategy for 2025.</p> <p>&nbsp;&nbsp;</p> <p>“<em>All of this potential doesn't matter if we don't turn it into something that creates value. And getting to those first applications are the value inflection points that we're aiming for this year. So a systematic platform approach but with a focus on getting to market in the high valuable compounds / chemicals spaces first and then the extraordinary business opportunities that, for example, is the isobutanol and sustainable aviation fuel where we have a partner in the US government that wants to and needs to see that happen and therefore is willing to sponsor that whole area.</em>” said Heltzen.</p> <p>&nbsp;</p> <p>Stay tuned for Part 4 - “looking ath the rest of 2025”. And please remember to follow Michael Heltzen and Invizyne to be sure to get all future updates as well!</p> </p><p><a href="http://exozymes.twentythree.com/go-to-market-strategy-part-3-of-a-1"><img src="http://exozymes.twentythree.com/64968570/108762670/d77f97fe83a44190f4bec5960b963a83/standard/download-15-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/photo/108762670 Wed, 15 Jan 2025 23:19:49 GMT Go To Market Strategy - part 3 of a fireside chat about Invizyne In this video - recorded on Dec 29, 2024 - MDB Capital Group’sLouBaseneseinterviewsInvizyne Technologies’ CEOMichael Heltzenabout the Invizyne’s Go To Market strategy for 2025. “All of this potential doesn't matter if we don't turn it into something that creates value. And getting to those first applications are the value inflection points that we're aiming for this year. So a systematic platform approach but with a focus on getting to market in the high valuable compounds / chemicals spaces first and then the extraordinary business opportunities that, for example, is the isobutanol and sustainable aviation fuel where we have a partner in the US government that wants to and needs to see that happen and therefore is willing to sponsor that whole area.” said Heltzen. Stay tuned for Part 4 - “looking ath the rest of 2025”. And please remember to follow Michael Heltzen and Invizyne to be sure to get all future updates as well! In this video - recorded on Dec 29, 2024 - MDB Capital Group’sLouBaseneseinterviewsInvizyne Technologies’ CEOMichael Heltzenabout the Invizyne’s Go To Market strategy for 2025. “All of this potential doesn't matter if we don't turn it into... eXoZymes 13:00 <p><p>In this video - recorded on Dec 29, 2024 - MDB Capital Group’s&nbsp;Lou&nbsp;Basenese&nbsp;interviews&nbsp;Invizyne Technologies’ CEO&nbsp;Michael Heltzen&nbsp;about the Invizyne’s Go To Market strategy for 2025.</p> <p>&nbsp;&nbsp;</p> <p>“<em>All of this potential doesn't matter if we don't turn it into something that creates value. And getting to those first applications are the value inflection points that we're aiming for this year. So a systematic platform approach but with a focus on getting to market in the high valuable compounds / chemicals spaces first and then the extraordinary business opportunities that, for example, is the isobutanol and sustainable aviation fuel where we have a partner in the US government that wants to and needs to see that happen and therefore is willing to sponsor that whole area.</em>” said Heltzen.</p> <p>&nbsp;</p> <p>Stay tuned for Part 4 - “looking ath the rest of 2025”. And please remember to follow Michael Heltzen and Invizyne to be sure to get all future updates as well!</p> </p><p><a href="http://exozymes.twentythree.com/go-to-market-strategy-part-3-of-a-1"><img src="http://exozymes.twentythree.com/64968570/108762670/d77f97fe83a44190f4bec5960b963a83/standard/download-15-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/using-ai-for-enzyme-engineering <p><p>In this video - recorded on Dec 29, 2024 - MDB Capital Group’s&nbsp;Lou&nbsp;Basenese&nbsp;interviews&nbsp;Invizyne Technologies’ CEO&nbsp;Michael Heltzen&nbsp;about the core technology behind Invizyne's platform and how it's based on no less than four current Nobel Prizes in chemistry. &nbsp;</p> <p style="text-align: start">&nbsp;</p> <p style="text-align: start">What’s more, while everyone is preoccupied with talking about AI in terms of&nbsp;Nvidia Corp.’s&nbsp;(#NVDA) impressive growth, the two discuss how AI is also dramatically impacting and accelerating Invizyne’s enzyme engineering capabilities.</p> <p style="text-align: start">&nbsp;</p> <p style="text-align: start">“Why does this matter? It's a new generation of access to chemicals. A new way where we don't use oil as a starting point. What is chemistry? It's your good life. It's what you're wearing right now. It is the sofa behind you. It is the paint on your walls. It is the colors you see in all materials. It is also in your food and in your medicine, in the fragrance and the flavors that makes the good life,” said Heltzen.</p> <p style="text-align: start">&nbsp;</p> <p style="text-align: start">Stay tuned for Part 3 about Invizyne’s Go-To-Market strategy. And please remember to follow Michael Heltzen and Invizyne to be sure to get all future updates as well!</p> </p><p><a href="http://exozymes.twentythree.com/using-ai-for-enzyme-engineering"><img src="http://exozymes.twentythree.com/64968577/108565862/962749644efd386788ecf2c78e844eaa/standard/download-16-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/photo/108565862 Tue, 07 Jan 2025 15:28:42 GMT Using AI for Enzyme Engineering - part 2 of a fireside chat about Invizyne In this video - recorded on Dec 29, 2024 - MDB Capital Group’sLouBaseneseinterviewsInvizyne Technologies’ CEOMichael Heltzenabout the core technology behind Invizyne's platform and how it's based on no less than four current Nobel Prizes in chemistry. What’s more, while everyone is preoccupied with talking about AI in terms ofNvidia Corp.’s(#NVDA) impressive growth, the two discuss how AI is also dramatically impacting and accelerating Invizyne’s enzyme engineering capabilities. “Why does this matter? It's a new generation of access to chemicals. A new way where we don't use oil as a starting point. What is chemistry? It's your good life. It's what you're wearing right now. It is the sofa behind you. It is the paint on your walls. It is the colors you see in all materials. It is also in your food and in your medicine, in the fragrance and the flavors that makes the good life,” said Heltzen. Stay tuned for Part 3 about Invizyne’s Go-To-Market strategy. And please remember to follow Michael Heltzen and Invizyne to be sure to get all future updates as well! In this video - recorded on Dec 29, 2024 - MDB Capital Group’sLouBaseneseinterviewsInvizyne Technologies’ CEOMichael Heltzenabout the core technology behind Invizyne's platform and how it's based on no less than four current Nobel Prizes in... eXoZymes 08:27 <p><p>In this video - recorded on Dec 29, 2024 - MDB Capital Group’s&nbsp;Lou&nbsp;Basenese&nbsp;interviews&nbsp;Invizyne Technologies’ CEO&nbsp;Michael Heltzen&nbsp;about the core technology behind Invizyne's platform and how it's based on no less than four current Nobel Prizes in chemistry. &nbsp;</p> <p style="text-align: start">&nbsp;</p> <p style="text-align: start">What’s more, while everyone is preoccupied with talking about AI in terms of&nbsp;Nvidia Corp.’s&nbsp;(#NVDA) impressive growth, the two discuss how AI is also dramatically impacting and accelerating Invizyne’s enzyme engineering capabilities.</p> <p style="text-align: start">&nbsp;</p> <p style="text-align: start">“Why does this matter? It's a new generation of access to chemicals. A new way where we don't use oil as a starting point. What is chemistry? It's your good life. It's what you're wearing right now. It is the sofa behind you. It is the paint on your walls. It is the colors you see in all materials. It is also in your food and in your medicine, in the fragrance and the flavors that makes the good life,” said Heltzen.</p> <p style="text-align: start">&nbsp;</p> <p style="text-align: start">Stay tuned for Part 3 about Invizyne’s Go-To-Market strategy. And please remember to follow Michael Heltzen and Invizyne to be sure to get all future updates as well!</p> </p><p><a href="http://exozymes.twentythree.com/using-ai-for-enzyme-engineering"><img src="http://exozymes.twentythree.com/64968577/108565862/962749644efd386788ecf2c78e844eaa/standard/download-16-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/looking-back-at-2024-part-1-of-a-1 <p><p>In this video - recorded on Dec 29, 2024 - Lou Basenese interviews Michael Heltzen about going IPO and the current challenges in SynBio - and how Invizyne can alleviate them - among other interesting topics, including the introduction of a paradigm shift in biomanufacturing.</p> <p>&nbsp;</p> <p>“What does our technology do? We build biosolutions. Humankind has built a lot of things based on petrochemicals or things we have taken from nature and made into chemicals. We can make a new generation of that by re-engineering enzymes, putting them in a bioreactor, and making them produce all kind of chemicals that turns into products - like drugs, nutraceuticals, and all the way out to industrial chemicals like biofuels.” – states Michael Heltzen</p> <p>&nbsp;</p> <p>Please remember to follow Michael Heltzen and Invizyne, to be sure to get future updates as well!</p> </p><p><a href="http://exozymes.twentythree.com/looking-back-at-2024-part-1-of-a-1"><img src="http://exozymes.twentythree.com/64968578/108513507/e6f69d2cb3363b9c99ebe9d593ac788b/standard/download-18-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/photo/108513507 Thu, 02 Jan 2025 22:21:05 GMT Looking back at 2024 - part 1 of a fireside chat about Invizyne In this video - recorded on Dec 29, 2024 - Lou Basenese interviews Michael Heltzen about going IPO and the current challenges in SynBio - and how Invizyne can alleviate them - among other interesting topics, including the introduction of a paradigm shift in biomanufacturing. “What does our technology do? We build biosolutions. Humankind has built a lot of things based on petrochemicals or things we have taken from nature and made into chemicals. We can make a new generation of that by re-engineering enzymes, putting them in a bioreactor, and making them produce all kind of chemicals that turns into products - like drugs, nutraceuticals, and all the way out to industrial chemicals like biofuels.” – states Michael Heltzen Please remember to follow Michael Heltzen and Invizyne, to be sure to get future updates as well! In this video - recorded on Dec 29, 2024 - Lou Basenese interviews Michael Heltzen about going IPO and the current challenges in SynBio - and how Invizyne can alleviate them - among other interesting topics, including the introduction of a... eXoZymes 11:25 <p><p>In this video - recorded on Dec 29, 2024 - Lou Basenese interviews Michael Heltzen about going IPO and the current challenges in SynBio - and how Invizyne can alleviate them - among other interesting topics, including the introduction of a paradigm shift in biomanufacturing.</p> <p>&nbsp;</p> <p>“What does our technology do? We build biosolutions. Humankind has built a lot of things based on petrochemicals or things we have taken from nature and made into chemicals. We can make a new generation of that by re-engineering enzymes, putting them in a bioreactor, and making them produce all kind of chemicals that turns into products - like drugs, nutraceuticals, and all the way out to industrial chemicals like biofuels.” – states Michael Heltzen</p> <p>&nbsp;</p> <p>Please remember to follow Michael Heltzen and Invizyne, to be sure to get future updates as well!</p> </p><p><a href="http://exozymes.twentythree.com/looking-back-at-2024-part-1-of-a-1"><img src="http://exozymes.twentythree.com/64968578/108513507/e6f69d2cb3363b9c99ebe9d593ac788b/standard/download-18-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/invizyne-awarded-250k-voucher-from <p><p>CEO of Invizyne, Michael Heltzen, states, “As a part of our journey from developing brand new technology, isobutanol, that allows for Sustainable Aviation Fuel (SAF), we have been scaling up from micro-batches to bigger batches in the laboratory. To get to the future where there will be mass production, one of the steps in this journey is to get to a pilot plant. We are lucky and would like to announce that we have received support by the DoE through a voucher that allows us to spend $250,000 on specifically mapping out this road to a pilot plant.”</p> <p></p> <p>Invizyne's voucher is for 250K to complete a Pre-Development Planning for Biomanufacturing Infrastructure Projects to decarbonize industrial manufacturing, utilizing Invizyne’s Isobutanol technology to build a biomanufacturing infrastructure project that decarbonizes the chemical/fuel space. The Voucher Program is funded by the Bipartisan Infrastructure Law (BIL) and Inflation Reduction Act (IRA) as part of the Technology Commercialization Fund (TCF) and leverages the Department of Energy’s (DOE) partnership intermediary agreement with ENERGYWERX.</p> <p></p> <p>More details on the voucher program:</p> <p><a target="_blank" rel="noopener noreferrer nofollow" href="https://www.energy.gov/technologytransitions/articles/doe-announces-new-275m-voucher-program-bring-innovative-energy"><a href="https://www.energy.gov/technologytransitions/articles/doe-announces-new-275m-voucher-program-bring-innovative-energy">https://www.energy.gov/technologytransitions/articles/doe-announces-new-275m-voucher-program-bring-innovative-energy</a></a></p> <p>#biomanufacturing #nextgenbiomanufacturing #cellfree #enzymes #biochemistry #biochemicals #synbio #syntheticbiology #biosynthesis #simplepath #scalablebiochemistry #scalable #energytransition #sustainableaviationfuel #SAF #greentech #cleantech #isobutanol #biofuel</p> </p><p><a href="http://exozymes.twentythree.com/invizyne-awarded-250k-voucher-from"><img src="http://exozymes.twentythree.com/64968575/107225779/b96c14a6ced0e9262d3045cbb5c384bd/standard/download-18-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/photo/107225779 Wed, 04 Dec 2024 10:03:34 GMT Invizyne awarded $250K voucher from DoE CEO of Invizyne, Michael Heltzen, states, “As a part of our journey from developing brand new technology, isobutanol, that allows for Sustainable Aviation Fuel (SAF), we have been scaling up from micro-batches to bigger batches in the laboratory. To get to the future where there will be mass production, one of the steps in this journey is to get to a pilot plant. We are lucky and would like to announce that we have received support by the DoE through a voucher that allows us to spend $250,000 on specifically mapping out this road to a pilot plant.” Invizyne's voucher is for 250K to complete a Pre-Development Planning for Biomanufacturing Infrastructure Projects to decarbonize industrial manufacturing, utilizing Invizyne’s Isobutanol technology to build a biomanufacturing infrastructure project that decarbonizes the chemical/fuel space. The Voucher Program is funded by the Bipartisan Infrastructure Law (BIL) and Inflation Reduction Act (IRA) as part of the Technology Commercialization Fund (TCF) and leverages the Department of Energy’s (DOE) partnership intermediary agreement with ENERGYWERX. More details on the voucher program: https://www.energy.gov/technologytransitions/articles/doe-announces-new-275m-voucher-program-bring-innovative-energy #biomanufacturing #nextgenbiomanufacturing #cellfree #enzymes #biochemistry #biochemicals #synbio #syntheticbiology #biosynthesis #simplepath #scalablebiochemistry #scalable #energytransition #sustainableaviationfuel #SAF #greentech #cleantech #isobutanol #biofuel CEO of Invizyne, Michael Heltzen, states, “As a part of our journey from developing brand new technology, isobutanol, that allows for Sustainable Aviation Fuel (SAF), we have been scaling up from micro-batches to bigger batches in the laboratory.... eXoZymes 01:40 <p><p>CEO of Invizyne, Michael Heltzen, states, “As a part of our journey from developing brand new technology, isobutanol, that allows for Sustainable Aviation Fuel (SAF), we have been scaling up from micro-batches to bigger batches in the laboratory. To get to the future where there will be mass production, one of the steps in this journey is to get to a pilot plant. We are lucky and would like to announce that we have received support by the DoE through a voucher that allows us to spend $250,000 on specifically mapping out this road to a pilot plant.”</p> <p></p> <p>Invizyne's voucher is for 250K to complete a Pre-Development Planning for Biomanufacturing Infrastructure Projects to decarbonize industrial manufacturing, utilizing Invizyne’s Isobutanol technology to build a biomanufacturing infrastructure project that decarbonizes the chemical/fuel space. The Voucher Program is funded by the Bipartisan Infrastructure Law (BIL) and Inflation Reduction Act (IRA) as part of the Technology Commercialization Fund (TCF) and leverages the Department of Energy’s (DOE) partnership intermediary agreement with ENERGYWERX.</p> <p></p> <p>More details on the voucher program:</p> <p><a target="_blank" rel="noopener noreferrer nofollow" href="https://www.energy.gov/technologytransitions/articles/doe-announces-new-275m-voucher-program-bring-innovative-energy"><a href="https://www.energy.gov/technologytransitions/articles/doe-announces-new-275m-voucher-program-bring-innovative-energy">https://www.energy.gov/technologytransitions/articles/doe-announces-new-275m-voucher-program-bring-innovative-energy</a></a></p> <p>#biomanufacturing #nextgenbiomanufacturing #cellfree #enzymes #biochemistry #biochemicals #synbio #syntheticbiology #biosynthesis #simplepath #scalablebiochemistry #scalable #energytransition #sustainableaviationfuel #SAF #greentech #cleantech #isobutanol #biofuel</p> </p><p><a href="http://exozymes.twentythree.com/invizyne-awarded-250k-voucher-from"><img src="http://exozymes.twentythree.com/64968575/107225779/b96c14a6ced0e9262d3045cbb5c384bd/standard/download-18-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/nrel-doe-what-invizyne-is-working <p>Yannick Bomble, PhD, Group Research Manager III-Biological Science at NREL (DoE), states: "What Invizyne is working on is a game changer" ~excerpt from the full NREL interview, which can be seen here:<br> <a href="https://www.invizyne.com/nrel-interview">https://www.invizyne.com/nrel-interview</a></p><p><a href="http://exozymes.twentythree.com/nrel-doe-what-invizyne-is-working"><img src="http://exozymes.twentythree.com/64968568/103326717/e50eefae8eb1ac668222566d7be49d26/standard/download-14-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/photo/103326717 Fri, 02 Aug 2024 13:45:18 GMT NREL (DoE): What Invizyne is working on is a game changer Yannick Bomble, PhD, Group Research Manager III-Biological Science at NREL (DoE), states: "What Invizyne is working on is a game changer" ~excerpt from the full NREL interview, which can be seen here: https://www.invizyne.com/nrel-interview Yannick Bomble, PhD, Group Research Manager III-Biological Science at NREL (DoE), states: "What Invizyne is working on is a game changer" ~excerpt from the full NREL interview, which can be seen here: https://www.invizyne.com/nrel-interview eXoZymes 00:43 <p>Yannick Bomble, PhD, Group Research Manager III-Biological Science at NREL (DoE), states: "What Invizyne is working on is a game changer" ~excerpt from the full NREL interview, which can be seen here:<br> <a href="https://www.invizyne.com/nrel-interview">https://www.invizyne.com/nrel-interview</a></p><p><a href="http://exozymes.twentythree.com/nrel-doe-what-invizyne-is-working"><img src="http://exozymes.twentythree.com/64968568/103326717/e50eefae8eb1ac668222566d7be49d26/standard/download-14-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/interview-nrel-doe-working-with <p>NREL (DoE) working with Invizyne in their 'Advancing Clean Tech to Energize the Future' project - a fireside chat with Yannick Bomble, PhD, Group Research Manager III-Biological Science at NREL - and - Tyler Korman, PhD, VP of Research at Invizyne - as well as - Lou Basenese, President &amp; Chief Market Strategist at MDB.</p><p><a href="http://exozymes.twentythree.com/interview-nrel-doe-working-with"><img src="http://exozymes.twentythree.com/64968568/103267739/b1d5066de05c47fc846cfebc5e2b7084/standard/download-31-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/photo/103267739 Fri, 02 Aug 2024 00:05:48 GMT Interview: NREL (DoE) working with Invizyne NREL (DoE) working with Invizyne in their 'Advancing Clean Tech to Energize the Future' project - a fireside chat with Yannick Bomble, PhD, Group Research Manager III-Biological Science at NREL - and - Tyler Korman, PhD, VP of Research at Invizyne - as well as - Lou Basenese, President Chief Market Strategist at MDB. NREL (DoE) working with Invizyne in their 'Advancing Clean Tech to Energize the Future' project - a fireside chat with Yannick Bomble, PhD, Group Research Manager III-Biological Science at NREL - and - Tyler Korman, PhD, VP of Research at Invizyne... eXoZymes 36:53 <p>NREL (DoE) working with Invizyne in their 'Advancing Clean Tech to Energize the Future' project - a fireside chat with Yannick Bomble, PhD, Group Research Manager III-Biological Science at NREL - and - Tyler Korman, PhD, VP of Research at Invizyne - as well as - Lou Basenese, President &amp; Chief Market Strategist at MDB.</p><p><a href="http://exozymes.twentythree.com/interview-nrel-doe-working-with"><img src="http://exozymes.twentythree.com/64968568/103267739/b1d5066de05c47fc846cfebc5e2b7084/standard/download-31-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/commercializing-invizynes-cell-free <p>Commercializing Invizyne’s cell-free platform - fireside chat withZachary Karl, PhD, Vice President of Business Development at Invizyne - and - Lou Basenese President & Chief Market Strategist at MDB Capital</p><p><a href="http://exozymes.twentythree.com/commercializing-invizynes-cell-free"><img src="http://exozymes.twentythree.com/64968561/103268098/11ab55fc737713ecb6af9fe545107029/standard/download-25-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/photo/103268098 Tue, 30 Jul 2024 00:59:46 GMT Commercializing Invizyne’s cell-free platform - fireside chat Commercializing Invizyne’s cell-free platform - fireside chat withZachary Karl, PhD, Vice President of Business Development at Invizyne - and - Lou Basenese President & Chief Market Strategist at MDB Capital Commercializing Invizyne’s cell-free platform - fireside chat withZachary Karl, PhD, Vice President of Business Development at Invizyne - and - Lou Basenese President & Chief Market Strategist at MDB Capital eXoZymes 56:48 <p>Commercializing Invizyne’s cell-free platform - fireside chat withZachary Karl, PhD, Vice President of Business Development at Invizyne - and - Lou Basenese President & Chief Market Strategist at MDB Capital</p><p><a href="http://exozymes.twentythree.com/commercializing-invizynes-cell-free"><img src="http://exozymes.twentythree.com/64968561/103268098/11ab55fc737713ecb6af9fe545107029/standard/download-25-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/invizyne-ipo-kol-call-with-dr <p>MDB Capital President and Chief Market Strategist Lou Basenese talks with Dr. James J. Lalonde, a recognized leader in the field of synthetic biology and Invizyne board member on July 17, 2024.<br><p><i>Invizyne is a leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercially important molecules and chemicals for everyday life, which recently filed a registration statement for an initial public offering (IPO). MDB Capital is acting as the sole underwriter for the offering.</i><br></p><p><i>​</i><br></p><p><i>The information contained in this presentation has been prepared to assist interested parties in making their own evaluation of the investment opportunity related to the Company and does not purport to be all-inclusive or to contain all of the information that a prospective investor may desire. In all cases, interested parties should conduct their own investigation and analysis of the data set forth in this presentation and the registration statement for the offering. The Company has not assumed any responsibility for independent verification of any of the forward-looking information contained in this presentation or the related registration statement, including projections and future events and assumptions on which the projections and future events are based. None of the Company or their respective affiliates and representatives makes any representation or warranty (expressed or implied) as to the accuracy or completeness of the forward-looking information contained in this presentation and the related registration statement. Those parties or entities expressly disclaim any and all liability based on or relating to any representations or warranties (expressed or implied) contained in, or errors or omission from, this presentation and the related registration statement or based on or relating to the recipient’s use or the use by any of its affiliates or representatives of this presentation or the related the registration statement or any other written or oral communications transmitted to the recipient or any of its affiliates or representatives in the course of its investment evaluation related to this investment opportunity.</i></p><p><br></p><p><span><i>The offering will be made only by means of a prospectus forming a part of the registration statement on Form S-1 relating to these securities that has been filed by the Company with the U.S. Securities and Exchange Commission but has not become effective. The common stock of Invizyne Technologies, Inc. may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. For additional information on Invizyne Technologies, Inc. and the offering, please review the current registration statement on Form S-1 (# 333-276987) that can be found at SEC.gov EDGAR Entity Landing Page:&nbsp;</i><a><i>sec.gov/edgar/search/#/ciks=0002010788</i></a><i>. A prospectus may also be obtained from MDB Capital by writing to MDB Capital, Prospectus Department, 14135 Midway Road, Suite G-150, Addison, Texas 75001 or emailing&nbsp;</i><a><i>community@mdb.com</i></a><i>.</i></span></p><p><br></p><p><i>Securities offered by the Company are highly speculative. Investing in the shares of common stock of the Company involves significant risks. The investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that an investment in the Company common stock could be illiquid for an indefinite period of time.</i></p><p><i>Prior to this offering, there has been no public market for the shares of common stock of the Company. The Company has applied to list its shares of common stock on the Nasdaq Capital Market, sometimes referred to as “Nasdaq.” The listing will not be approved until the time of the offering. No assurance can be given that the application will be approved or that an active trading market for the shares of common stock will develop. The Company will not consummate and close this offering without a listing approval letter from Nasdaq. If the Company does not receive a Nasdaq listing approval, they will terminate the offering.</i></p><p><i>MDB Capital is required to provide you with certain disclosures and informational resources pertaining to your account and investment activity.</i></p><p><span><i>Please follow the link below to review MDB Capital’s Form CRS and additional relevant disclosures:</i><br><a><i>mdb.com/disclosures</i></a><i>.</i></span></p><p><span><i>NOTICE: Securities trading, account management, and investment banking services are offered by MDB Capital, a registered broker-dealer and member of FINRA and SIPC. Unless clearly stated, nothing herein shall be construed to be an offer to sell, nor a solicitation of an offer to buy, any financial product.</i></span></p></p><p><a href="http://exozymes.twentythree.com/invizyne-ipo-kol-call-with-dr"><img src="http://exozymes.twentythree.com/64968559/103022799/3607370a1c9ec6e7d04c093d1c2a0bef/standard/download-34-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/photo/103022799 Mon, 22 Jul 2024 21:15:46 GMT Invizyne IPO - KOL Call with Dr. James J. Lalonde (July 17, 2024) MDB Capital President and Chief Market Strategist Lou Basenese talks with Dr. James J. Lalonde, a recognized leader in the field of synthetic biology and Invizyne board member on July 17, 2024.Invizyne is a leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercially important molecules and chemicals for everyday life, which recently filed a registration statement for an initial public offering (IPO). MDB Capital is acting as the sole underwriter for the offering.​The information contained in this presentation has been prepared to assist interested parties in making their own evaluation of the investment opportunity related to the Company and does not purport to be all-inclusive or to contain all of the information that a prospective investor may desire. In all cases, interested parties should conduct their own investigation and analysis of the data set forth in this presentation and the registration statement for the offering. The Company has not assumed any responsibility for independent verification of any of the forward-looking information contained in this presentation or the related registration statement, including projections and future events and assumptions on which the projections and future events are based. None of the Company or their respective affiliates and representatives makes any representation or warranty (expressed or implied) as to the accuracy or completeness of the forward-looking information contained in this presentation and the related registration statement. Those parties or entities expressly disclaim any and all liability based on or relating to any representations or warranties (expressed or implied) contained in, or errors or omission from, this presentation and the related registration statement or based on or relating to the recipient’s use or the use by any of its affiliates or representatives of this presentation or the related the registration statement or any other written or oral communications transmitted to the recipient or any of its affiliates or representatives in the course of its investment evaluation related to this investment opportunity.The offering will be made only by means of a prospectus forming a part of the registration statement on Form S-1 relating to these securities that has been filed by the Company with the U.S. Securities and Exchange Commission but has not become effective. The common stock of Invizyne Technologies, Inc. may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. For additional information on Invizyne Technologies, Inc. and the offering, please review the current registration statement on Form S-1 (# 333-276987) that can be found at SEC.gov EDGAR Entity Landing Page:sec.gov/edgar/search/#/ciks=0002010788. A prospectus may also be obtained from MDB Capital by writing to MDB Capital, Prospectus Department, 14135 Midway Road, Suite G-150, Addison, Texas 75001 or emailingcommunity@mdb.com.Securities offered by the Company are highly speculative. Investing in the shares of common stock of the Company involves significant risks. The investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that an investment in the Company common stock could be illiquid for an indefinite period of time.Prior to this offering, there has been no public market for the shares of common stock of the Company. The Company has applied to list its shares of common stock on the Nasdaq Capital Market, sometimes referred to as “Nasdaq.” The listing will not be approved until the time of the offering. No assurance can be given that the application will be approved or that an active trading market for the shares of common stock will develop. The Company will not consummate and close this offering without a listing approval letter from Nasdaq. If the Company does not receive a Nasdaq listing approval, they will terminate the offering.MDB Capital is required to provide you with certain disclosures and informational resources pertaining to your account and investment activity.Please follow the link below to review MDB Capital’s Form CRS and additional relevant disclosures:mdb.com/disclosures.NOTICE: Securities trading, account management, and investment banking services are offered by MDB Capital, a registered broker-dealer and member of FINRA and SIPC. Unless clearly stated, nothing herein shall be construed to be an offer to sell, nor a solicitation of an offer to buy, any financial product. MDB Capital President and Chief Market Strategist Lou Basenese talks with Dr. James J. Lalonde, a recognized leader in the field of synthetic biology and Invizyne board member on July 17, 2024.Invizyne is a leading designer of cell-free,... eXoZymes 37:21 <p>MDB Capital President and Chief Market Strategist Lou Basenese talks with Dr. James J. Lalonde, a recognized leader in the field of synthetic biology and Invizyne board member on July 17, 2024.<br><p><i>Invizyne is a leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercially important molecules and chemicals for everyday life, which recently filed a registration statement for an initial public offering (IPO). MDB Capital is acting as the sole underwriter for the offering.</i><br></p><p><i>​</i><br></p><p><i>The information contained in this presentation has been prepared to assist interested parties in making their own evaluation of the investment opportunity related to the Company and does not purport to be all-inclusive or to contain all of the information that a prospective investor may desire. In all cases, interested parties should conduct their own investigation and analysis of the data set forth in this presentation and the registration statement for the offering. The Company has not assumed any responsibility for independent verification of any of the forward-looking information contained in this presentation or the related registration statement, including projections and future events and assumptions on which the projections and future events are based. None of the Company or their respective affiliates and representatives makes any representation or warranty (expressed or implied) as to the accuracy or completeness of the forward-looking information contained in this presentation and the related registration statement. Those parties or entities expressly disclaim any and all liability based on or relating to any representations or warranties (expressed or implied) contained in, or errors or omission from, this presentation and the related registration statement or based on or relating to the recipient’s use or the use by any of its affiliates or representatives of this presentation or the related the registration statement or any other written or oral communications transmitted to the recipient or any of its affiliates or representatives in the course of its investment evaluation related to this investment opportunity.</i></p><p><br></p><p><span><i>The offering will be made only by means of a prospectus forming a part of the registration statement on Form S-1 relating to these securities that has been filed by the Company with the U.S. Securities and Exchange Commission but has not become effective. The common stock of Invizyne Technologies, Inc. may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. For additional information on Invizyne Technologies, Inc. and the offering, please review the current registration statement on Form S-1 (# 333-276987) that can be found at SEC.gov EDGAR Entity Landing Page:&nbsp;</i><a><i>sec.gov/edgar/search/#/ciks=0002010788</i></a><i>. A prospectus may also be obtained from MDB Capital by writing to MDB Capital, Prospectus Department, 14135 Midway Road, Suite G-150, Addison, Texas 75001 or emailing&nbsp;</i><a><i>community@mdb.com</i></a><i>.</i></span></p><p><br></p><p><i>Securities offered by the Company are highly speculative. Investing in the shares of common stock of the Company involves significant risks. The investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that an investment in the Company common stock could be illiquid for an indefinite period of time.</i></p><p><i>Prior to this offering, there has been no public market for the shares of common stock of the Company. The Company has applied to list its shares of common stock on the Nasdaq Capital Market, sometimes referred to as “Nasdaq.” The listing will not be approved until the time of the offering. No assurance can be given that the application will be approved or that an active trading market for the shares of common stock will develop. The Company will not consummate and close this offering without a listing approval letter from Nasdaq. If the Company does not receive a Nasdaq listing approval, they will terminate the offering.</i></p><p><i>MDB Capital is required to provide you with certain disclosures and informational resources pertaining to your account and investment activity.</i></p><p><span><i>Please follow the link below to review MDB Capital’s Form CRS and additional relevant disclosures:</i><br><a><i>mdb.com/disclosures</i></a><i>.</i></span></p><p><span><i>NOTICE: Securities trading, account management, and investment banking services are offered by MDB Capital, a registered broker-dealer and member of FINRA and SIPC. Unless clearly stated, nothing herein shall be construed to be an offer to sell, nor a solicitation of an offer to buy, any financial product.</i></span></p></p><p><a href="http://exozymes.twentythree.com/invizyne-ipo-kol-call-with-dr"><img src="http://exozymes.twentythree.com/64968559/103022799/3607370a1c9ec6e7d04c093d1c2a0bef/standard/download-34-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/the-story-of-exozymes-interview <p><p>Interviews with eXoZymes co-founders, Tyler Korman, PhD - and - Paul Opgenorth, PhD, sharing how the basic idea - liberating the enzymes from the confines of working in cells - was hatched in Jim Bowie's lab at UCLA, before being spun out as Invizyne Technologies in 2019 (rebranded to eXoZymes in 2025), including some of the projects and challenges along the way.</p></p><p><a href="http://exozymes.twentythree.com/the-story-of-exozymes-interview"><img src="http://exozymes.twentythree.com/64968561/100951904/b84ec0d789f34490d6fac2a00e33164c/standard/download-45-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/photo/100951904 Wed, 22 May 2024 16:33:18 GMT The story of eXoZymes: Interview with Tyler Korman and Paul Opgenorth Interviews with eXoZymes co-founders, Tyler Korman, PhD - and - Paul Opgenorth, PhD, sharing how the basic idea - liberating the enzymes from the confines of working in cells - was hatched in Jim Bowie's lab at UCLA, before being spun out as Invizyne Technologies in 2019 (rebranded to eXoZymes in 2025), including some of the projects and challenges along the way. Interviews with eXoZymes co-founders, Tyler Korman, PhD - and - Paul Opgenorth, PhD, sharing how the basic idea - liberating the enzymes from the confines of working in cells - was hatched in Jim Bowie's lab at UCLA, before being spun out as... eXoZymes 06:56 <p><p>Interviews with eXoZymes co-founders, Tyler Korman, PhD - and - Paul Opgenorth, PhD, sharing how the basic idea - liberating the enzymes from the confines of working in cells - was hatched in Jim Bowie's lab at UCLA, before being spun out as Invizyne Technologies in 2019 (rebranded to eXoZymes in 2025), including some of the projects and challenges along the way.</p></p><p><a href="http://exozymes.twentythree.com/the-story-of-exozymes-interview"><img src="http://exozymes.twentythree.com/64968561/100951904/b84ec0d789f34490d6fac2a00e33164c/standard/download-45-thumbnail.jpg" width="75" height=""/></a></p> cannabinoids founder interview invizyne isobutanol jim bowie paul opgenorth SAF sustainable aviation fuel tyler korman